Kiniksa Pharmaceuticals International PLC
(NAS:KNSA)
$
27.655
0.275 (1%)
Market Cap: 1.97 Bil
Enterprise Value: 1.74 Bil
PE Ratio: 0
PB Ratio: 4.52
GF Score: 58/100 Kiniksa Pharmaceuticals International PLC (KNSA) Transcripts
- Q2 2024 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptJul 23, 2024$26.29 (+22.91%)Earnings
- Q1 2024 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptApr 23, 2024$17.68 (+3.42%)Earnings
- Q4 2023 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptFeb 28, 2024$20.36 (-2.54%)Earnings
- Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Q3 2023 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptOct 31, 2023$15.25 (-2.74%)Earnings
- Q2 2023 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptJul 25, 2023$19.48 (+30.39%)Earnings
- Kiniksa Pharmaceuticals Ltd at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Q1 2023 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptMay 02, 2023$12.59 (+14.66%)Earnings
- Q4 2022 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptFeb 28, 2023$12.86 (-3.45%)Earnings
- Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Kiniksa Pharmaceuticals Ltd at Bank of America Biotech SMID Cap Conference TranscriptDec 07, 2022
- Q3 2022 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptNov 01, 2022$12.8 (+12.08%)Earnings
- Q2 2022 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptAug 03, 2022$10.68 (+7.12%)Earnings
- Q1 2022 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptMay 03, 2022$10.11 (+7.44%)Earnings
- Q4 2021 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptFeb 22, 2022$10.62 (-0.93%)Earnings
- Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Q3 2021 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptNov 01, 2021$12.73 (+22.52%)Earnings
- Q2 2021 Kiniksa Pharmaceuticals Ltd Earnings Call TranscriptAug 03, 2021$13.69 (-15.65%)Earnings
- Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- Kiniksa Pharmaceuticals Ltd FDA Approval of ARCALYST (rilonacept) for Recurrent Pericarditis Conference Call TranscriptMar 18, 2021
- Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Kiniksa Pharmaceuticals Ltd Rilonacept Analyst Day TranscriptSep 29, 2020
- Kiniksa Pharmaceuticals Ltd at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- Kiniksa Pharmaceuticals Ltd Annual Shareholders Meeting TranscriptJun 30, 2020
- Kiniksa Pharmaceuticals, Ltd. - Special Call TranscriptJun 29, 2020
- Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference TranscriptJan 13, 2020
- Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 11, 2019
- Kiniksa Pharmaceuticals Ltd at Barclays Global Healthcare Conference TranscriptMar 12, 2019
- 1